Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration

. 2024 Nov 21 ; 14 (1) : 28902. [epub] 20241121

Jazyk angličtina Země Velká Británie, Anglie Médium electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid39572693

Grantová podpora
17-29241A Ministerstvo Zdravotnictví Ceské Republiky
CZ.02.01.01/00/22_008/0004607 European Union

Odkazy

PubMed 39572693
PubMed Central PMC11582623
DOI 10.1038/s41598-024-80375-5
PII: 10.1038/s41598-024-80375-5
Knihovny.cz E-zdroje

Age-related macular degeneration (AMD) is a progressive chronic disease causing visual impairment or central vision loss in the elderly. We hypothesized that successful rheopheresis would be associated with positive changes in soluble endoglin (sENG), PSCK9, alpha-2-macroglobulin (A2M), and hs-CRP levels. 31 elderly patients with the dry form of AMD, treated with rheopheresis with a follow-up period of at least 5 years and an average age of 68 ± 4 years, were evaluated. Each treated patient received a series of 8 procedures in 10 weeks and, after the 2-year period, another 2 procedures within 1 week. Then, the patients were followed up every 6 months and divided into the successfully treated and therapeutic failure group according to best-corrected visual acuity (BCVA), size of the drusen area, and the drusenoid pigment epithelium detachment (DPED). Based on the ophthalmological assessment, rheopheresis treatment was successful in 73% of AMD patients. The therapy was associated with a significant decrease in total cholesterol, LDL-C, HDL-C, apoprotein B, lipoprotein (a) levels, and rheologically important parameters, irrespective of the therapy's success or failure. The success of rheopheresis therapy was exclusively related to a significant decrease in sENG and A2M levels. Over the long term, rheopheresis prevented the decline of BCVA, reduced the DPED and area of macular drusen, and improved the preservation of an intact photoreceptor ellipsoid zone in most patients. Moreover, we showed for the first time that sENG and A2M could be potentially sensitive biomarkers of successful rheopheresis procedure, irrespective of lipid parameters changes.

Zobrazit více v PubMed

Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. PubMed DOI

Roizenblatt, M., Naranjit, N., Maia, M. & Gehlbach, P. L. The question of a role for statins in age-related macular degeneration. PubMed DOI PMC

Tserentsoodol, N. et al. Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. PubMed

Fliesler, S. J., Florman, R., Rapp, L. M., Pittler, S. J. & Keller, R. K. In vivo biosynthesis of cholesterol in the rat retina. PubMed DOI

Tserentsoodol, N. et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. PubMed

Klein, R. et al. Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study. PubMed DOI PMC

Lehmann, G. L. et al. Retinal pigment epithelium-secreted VEGF-A induces alpha-2-macroglobulin expression in endothelial cells. PubMed DOI PMC

Blazquez-Medela, A. M. et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. PubMed DOI PMC

Kaitu’u-Lino, T. J. et al. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. PubMed DOI

Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familiar hypercholesterolemia. PubMed DOI

Blann, A. D., Wang, J. M., Wilson, P. B. & Kumar, S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. PubMed DOI

Malhotra, R. et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. PubMed DOI PMC

Leanos-Miranda, A. et al. Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. PubMed DOI

Rathouska, J., Jezkova, K., Nemeckova, I. & Nachtigal, P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. PubMed DOI

Vitverova, B. et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. PubMed DOI

Klingel, R., Fassbender, C., Fassbender, T. & Gohlen, B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. PubMed DOI

Borberg, H. & Tauchert, M. Rheohaemapheresis of ophthalmological diseases and diseases of the microcirculation. PubMed DOI

Zion, I. B. et al. Pulsatile ocular blood flow: relationship with flow velocities in vessels supplying the retina and choroid. PubMed DOI PMC

Klingel, R. et al. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. PubMed DOI

Langrova, H. et al. Rheopheresis in the treatment of age-related macular degeneration. PubMed

Rencova, E. et al. Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of age-related macular degeneration 2.5 years after rheohemapheresis. PubMed DOI

Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. PubMed DOI

Studnicka, J. et al. Long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration. PubMed DOI PMC

Visek, J. et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. PubMed DOI PMC

Blaha, M. et al. Changes of the complement system and rheological indicators after therapy with rheohemapheresis. PubMed DOI

Tavori, H., Giunzioni, I., Linton, M. F. & Fazio, S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. PubMed DOI PMC

Augood, C. et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. PubMed DOI

Rencova, E. et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. PubMed DOI

Blaha, M. et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. PubMed DOI

Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The seventh special issue. PubMed

Blaha, V. et al. Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis. PubMed DOI

Pulido, J. S., Multicenter Investigation of Rheopheresis for AMDSG. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. PubMed PMC

Blaha, M. et al. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). PubMed DOI

Rencova, E. et al. Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis. PubMed DOI PMC

Snow, K. K. & Seddon, J. M. Do age-related macular degeneration and cardiovascular disease share common antecedents?. PubMed DOI

Connelly-Smith, L. et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American society for apheresis: The ninth special issue. PubMed DOI

Pennington, K. L. & DeAngelis, M. M. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. PubMed DOI PMC

Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. PubMed DOI

Vicen, M. et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. PubMed DOI

Strasky, Z. et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. PubMed DOI

Calabro, P., Golia, E. & Yeh, E. T. CRP and the risk of atherosclerotic events. PubMed DOI

Shijo, T. et al. Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration. PubMed DOI

Vandooren, J. & Itoh, Y. Alpha-2-macroglobulin in inflammation immunity and infections. PubMed DOI PMC

Mantuano, E. et al. LDL receptor-related protein-1 regulates NFkappaB and microRNA-155 in macrophages to control the inflammatory response. PubMed DOI PMC

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...